The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
Crossover hits overall survival, pouring doubts on the group’s deal hopes.
Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.
After a rollercoaster existence Cellular Biomedicine Group has a new name, and new deals with AstraZeneca and J&J.
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
Yet another rich ADC deal is struck as Bristol Myers Squibb ties up with China’s SystImmune.
The group highlights safety and manufacturability, as well as efficacy, but investors apparently have doubts.